Business Wire

NY-TAKEDA/NY-ACADEMY

Share
Takeda and the New York Academy of Sciences Announce 2019 Innovators in Science Award Winners

Takeda Pharmaceutical Company Limited, (“Takeda”) (TSE:4502 ) and the New York Academy of Sciences announced today the Winners of the second annual Innovators in Science Award for their commitment to and excellence in regenerative medicine.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181212005061/en/

The 2019 Winner of the Senior Scientist Award is Michele De Luca, M.D., Professor of Biochemistry and Director of the Centre for Regenerative Medicine “Stefano Ferrari”, University of Modena and Reggio Emilia in Modena, Italy. Dr. De Luca has dedicated his career in translational medicine to developing stem cell therapies and is a leading authority on human squamous epithelial stem cell biology.

“Breakthroughs in regenerative medicine start with basic science and developmental biology. It’s an honor to be recognized for my research in epithelial stem cells and for my contributions in expanding their therapeutic potential,” said Dr. De Luca. “The award is an urging motivator to continue pursuing this line of research to hopefully turn promising research into real, life-saving therapies.”

The 2019 Winner of the Early-Career Scientist Award is Shruti Naik, Ph.D., Assistant Professor, Departments of Pathology, Medicine and Dermatology, NYU School of Medicine in the United States. Dr. Naik studies immune cell, epithelial cell and microbial interactions to inform therapeutic strategies for conditions such as psoriasis, chronic wounds and cancer.

“I’m truly honored to receive this award and to showcase progress in regenerative medicine on a global platform,” said Dr. Naik. “This recognition provides an opportunity to build collaborations with world-leading researchers as we further appreciate the complexities of stem cells and what they mean for regenerative medicine and future therapies.”

The 2019 Winners will be honored at the Innovators in Science Award Ceremony and Symposium in April 2019 in Japan.

“The transformative power of cell therapies will enable a new generation of innovative medicines for patients across a range of diseases, and Takeda is committed to nurturing this advancing area of science both within and outside our four walls,” said Andrew Plump, M.D., Ph.D., Chief Medical and Scientific Officer for Takeda. “We are proud to honor the work of this year’s Innovators in Science Award Winners, which is driving meaningful advancements in regenerative medicine.”

“Solutions to society’s biggest challenges in medicine will come from those working at the forefront of science,” stated Ellis Rubinstein, President and CEO, the New York Academy of Sciences. “Regenerative medicine offers a new frontier of discovery with unlimited potential to change lives for the better. We’re proud to partner with Takeda for a second year to grant the Innovators in Science Award to early-career and senior scientists, and to recognize pioneers in medical innovation across a variety of fields.”

The Innovators in Science Award, conferred in partnership between Takeda and the New York Academy of Sciences, recognizes and celebrates disruptive and transformative research in areas including: gastroenterology, neuroscience, oncology and regenerative medicine.

About the Innovators in Science Award
The Innovators in Science Award grants two prizes of US $200,000 each year: one to an Early-Career Scientist and the other to a well-established Senior Scientist who have distinguished themselves for the creative thinking and impact of their research. The Innovators in Science Award is a limited submission competition in which research universities, academic institutions, government or non-profit institutions, or equivalent from around the globe with a well-established record of scientific excellence are invited to nominate their most promising Early-Career Scientists and their most outstanding Senior Scientists working in one of four selected therapeutic fields of neuroscience, gastroenterology, oncology, and regenerative medicine. Prize Winners are determined by a panel of judges, independently selected by the New York Academy of Sciences, with expertise in these disciplines. The New York Academy of Sciences administers the Award in partnership with Takeda. For more information please visit the Innovators in Science Award website .

About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502 ) is a global, research and development-driven pharmaceutical company committed to bringing better health and a brighter future to patients by translating science into life-changing medicines. Takeda focuses its R&D efforts on oncology, gastroenterology and neuroscience therapeutic areas plus vaccines. Takeda conducts R&D both internally and with partners to stay at the leading edge of innovation. Innovative products, especially in oncology and gastroenterology, as well as Takeda’s presence in emerging markets, are currently fueling the growth of Takeda. Approximately 30,000 Takeda employees are committed to improving quality of life for patients, working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/

About the New York Academy of Sciences
The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology, and society worldwide. With more than 20,000 members in 100 countries around the world, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at www.nyas.org .

Contact:

The New York Academy of Sciences Marie Gentile mgentile@nyas.org Takeda Pharmaceutical Company Limited Kerry Bryant kerry.bryant@takeda.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

KuppingerCole Recognizes Regula as One of the Innovation Leaders in Identity Verification10.6.2025 03:00:00 CEST | Press release

Regula, a global developer of forensic devices and identity verification (IDV) solutions, has made its inaugural appearance in the KuppingerCole Leadership Compass for Identity Verification 2025. Mentioned in the Innovation Leaders category, the company is recognized for its 100% in-house R&D, forensic-grade technology, global document coverage, and advanced liveness detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609760424/en/ Regula’s innovative in-house technology powers fast, seamless identity checks—now recognized by KuppingerCole Analysts. Specializing in IDV and cybersecurity industry analysis, KuppingerCole forecasts that the global IDV market will grow from $18.4 billion in 2025 to $50.07 billion by 2030, driven by increasing identity fraud, compliance requirements, user expectations, and technological advancements. As identity verification rapidly shifts toward fully remote and automated e

IFF Appoints Virginia “Gina” Drosos to Board of Directors9.6.2025 23:46:00 CEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances, food ingredients, health and biosciences—today announced the appointment of Gina Drosos to its board of directors, effective June 16. Drosos brings more than 30 years of executive leadership experience across the retail, consumer goods, beauty and health care industries. “We are very pleased to welcome Gina to the IFF board,” said Kevin O’Byrne, chair of the board. “Gina brings extensive relevant experience, deep consumer insights and a proven ability to drive innovation and lead with purpose, which aligns with our long-term strategy to deliver sustainable growth and value creation for all stakeholders.” Drosos most recently served as chief executive officer and a director of Signet Jewelers Ltd. (NYSE: SIG)—the world’s largest retailer of diamond jewelry—from August 2017 to November 2024. During her tenure, she led the company through a significant transformation, expanding its digital capabilities and enhancing customer experien

Vantage Data Centers Completes Industry’s First Euro-Based Data Center Asset-Backed Securitization (ABS) with €640M Transaction9.6.2025 18:00:00 CEST | Press release

Incremental green financing will drive continued, sustainable developments across the refinanced portfolio Vantage Data Centers, a leading global provider of hyperscale data center campuses, today announced it has raised €640 million in securitized term notes, marking the first-ever euro-based securitization of data center assets in Continental Europe. The transaction includes an additional €80 million in unfunded Variable Funding Notes. The Class A-2 Notes are rated A-, and the Class B Notes are rated BBB- by Standard & Poor’s and Scope Ratings. This transaction follows Vantage’s success last year with the first-ever EMEA data center ABS completed in British pound sterling. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609592365/en/ Pictured is BER11, part of Vantage’s first Berlin campus located in Brandenburg Park. The notes will be used to refinance four data centers in Germany, two in Offenbach, Frankfurt, and two i

Uniphore Launches Business AI Cloud: A Sovereign, Composable & Secure AI Platform to Power the Agentic Enterprise9.6.2025 15:04:00 CEST | Press release

New platform unifies agents, models, knowledge, and data to finally deliver on the promise of AI as a transformative force for business Uniphore, the Business AI company, today launched the Uniphore Business AI Cloud: a sovereign, composable, and secure platform that bridges the “AI divide” between IT and business users by combining the simplicity of consumer AI with enterprise-grade security and scalability. While AI technologies rapidly reshape the enterprise, there has been little focus on deploying AI in a way that empowers CIOs to scale it securely across the organization while enabling business users to intuitively access AI with the full power of enterprise data, integrations, and context. IT and business must be united through a single AI platform to fulfill AI’s promise as a transformative force for business. Introducing the Business AI Cloud Uniphore’s Business AI Cloud powers the agentic enterprise with a full-stack AI platform spanning data, knowledge, models, and agents. I

Capcom’s Resident Evil Requiem, the Latest Title in the Series, Set to Release on February 27, 2026!9.6.2025 15:00:00 CEST | Press release

– The highly anticipated new installment to launch during the series’ 30th anniversary – Capcom Co., Ltd. (TOKYO:9697) today announced that Resident Evil Requiem, the latest title in the Resident Evil series, is scheduled for release on February 27, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250609946595/en/ Resident Evil Requiem Logo Resident Evil Requiem is a survival horror game that serves as the ninth main installment in the series. The title is being developed using RE ENGINE, Capcom’s proprietary game engine, and leverages Capcom’s extensive development expertise cultivated through numerous hit titles. The graphical fidelity has undergone a significant evolution in particular, delivering visuals with cinematic realism that vividly convey characters’ emotions and offer an unprecedented level of immersion. The company is developing the title steadily to meet the high expectations of both long-time series’ fans

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye